Johnson & Johnson vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?

Source The Motley Fool

Key Points

  • Johnson & Johnson offers a diversified healthcare portfolio and massive scale across its MedTech and pharmaceutical segments.

  • Vertex Pharmaceuticals maintains a dominant position in the cystic fibrosis market while expanding into high-growth gene therapies.

  • Which of these industry leaders is the better addition to your portfolio for 2027?

  • Motley Fool Issues Rare "Total Conviction" Buy Alert ›

Healthcare investors often choose between established stability and high-growth innovation. Determining whether Johnson & Johnson (NYSE:JNJ) or Vertex Pharmaceuticals (NASDAQ:VRTX) is the superior choice requires examining their financial health and long-term strategies.

Johnson & Johnson is a diversified giant pivoting toward its most profitable medical technology and innovative medicine segments. Vertex Pharmaceuticals is a specialized biotechnology leader that is successfully diversifying its pipeline beyond its core treatments. Both companies provide unique advantages for investors looking toward 2027.

The case for Johnson & Johnson

As a giant among healthcare stocks, the company focuses on its Innovative Medicine and MedTech segments to drive global growth. It distributes medications and devices to retailers, wholesalers, and hospitals, with a strategy centered on oncology, immunology, and neuroscience. Notable collaborations include an exclusive license for Darzalex from Genmab A/S (NASDAQ:GMAB) and a partnership with AbbVie (NYSE:ABBV) to co-commercialize the cancer drug Imbruvica.

In the 12 months ended Sept. 27, 2026, revenue reached about $99.3 billion, representing growth of roughly 7.8% compared to the prior period. During this same time frame, it reported net income of approximately $16.1 billion. This performance highlights the company's ability to maintain substantial revenue while navigating the complexities of the global medical marketplace.

As of its December 2025 balance sheet, the company maintains a debt-to-equity ratio of approximately 0.6x, which measures the balance between its total debt and shareholder equity. Its current ratio stands at nearly 1.0x, a metric that indicates whether a firm can cover its short-term obligations with its current assets. In the fiscal year ended Dec. 28, 2025, free cash flow was around $19.7 billion, providing ample capital for research and dividends.

The case for Vertex Pharmaceuticals

Vertex Pharmaceuticals dominates the market for cystic fibrosis treatments and is aggressively expanding into gene-editing and acute pain therapies. It primarily sells its products to specialty pharmacies and distributors that provide access to patients and healthcare providers worldwide. The company is also collaborating with CRISPR Therapeutics (NASDAQ:CRSP) to develop innovative therapies for serious blood disorders.

In the 12 months ended Sept. 30, 2026, revenue reached about $13.0 billion, which indicates a growth rate of roughly 10.5% over the previous twelve-month period. The company also reported net income of approximately $4.0 billion during this time. This steady growth reflects the strong demand for its specialized therapies and its successful efforts to broaden its clinical pipeline.

As of its December 2025 balance sheet, Vertex carries a debt-to-equity ratio of approximately 0.1x, reflecting a conservative use of borrowed funds. Its current ratio is roughly 2.9x, suggesting a strong ability to meet short-term financial commitments. In the fiscal year ended Dec. 31, 2025, free cash flow was around $3.2 billion, which supports its ongoing investment in research and development.

Risk profile comparison

Johnson & Johnson faces significant legal risks, particularly regarding product liability litigation for its talc-containing products. The company also deals with challenges to its intellectual property rights, as key products like Stelara face potential competition from biosimilars. Additionally, drug pricing reforms in the U.S. and the planned separation of its Orthopedics business introduce operational and strategic uncertainty.

Vertex Pharmaceuticals carries risks related to its high revenue concentration, as nearly all of its sales come from its cystic fibrosis franchise. The competitive landscape for biotechnology remains intense, and the company must navigate pricing pressures from government and commercial payors. Furthermore, the development of cell and gene therapies involves high regulatory uncertainty and significant financial investment in specialized manufacturing.

Valuation comparison

Johnson & Johnson currently trades at a more modest valuation than Vertex Pharmaceuticals based on its lower multiples for both future earnings and sales.

MetricJohnson & JohnsonVertex Pharmaceuticals
Forward P/E25.4x29.6x
P/S ratio6.8x10.5x

Valuation metrics include those sourced from Financial Modeling Prep (FMP) and may differ from those of other data providers.

The Forward P/E ratio compares a company's current stock price to its earnings estimates for the next twelve months. The P/S ratio measures the market value of the company relative to its sales over the past twelve months.

Which stock would I buy for 2027?

Johnson & Johnson is an overlooked behemoth compared with faster-growing biotech companies. The business has 28 products and platforms that generate more than $1 billion in annual revenue. Its pharmaceuticals arm, Innovative Medicine, has received two FDA approvals this year and has two more approved drug product launches in the E.U. and the U.S. The Innovative Medicine division accounts for 65% of JNJ's annual revenue and appears to have a robust pipeline beyond the pending products. MedTech, its other arm, sells a wide range of healthcare products, including wound care, surgical instruments and implants, hip and knee replacements, and spinal implants. The recent buy of Atraverse Medical bolsters that business. Revenue for Johnson & Johnson is expected to rise to $101 billion in the current fiscal year. However, Wall Street anticipates a $10 billion drop in net income, to around $16.6 billion.

Vertex Pharmaceuticals continues to benefit from its focus on cystic fibrosis (CF). It recently launched Alyftrek, a once-daily, next-in-class, triple-combination CF regimen. The treatment is seen encouragingly by investors. Alyftrek marks a notable improvement to the twice-daily dosage of Vertex's other CF products and was approved in Australia, New Zealand, Switzerland, the European Union, the U.K., and Canada over the course of 2025, after the U.S. approved it in 2024. Plenty more jurisdictions are evaluating the treatment today. In the U.S., label extensions (the expansion of FDA approval for use) mean Vertex can treat 95% of people with cystic fibrosis in the country today.

Vertex has expanded into treating other conditions. Povetacicept, an investigational recombinant fusion protein therapeutic, continues to show best-in-class potential as a treatment for three chronic autoimmune diseases: IgA nephropathy (IgAN), primary membranous nephropathy (pMN), and generalized myasthenia gravis (gMG). The FDA has granted its Breakthrough Therapy Designation for IgAN, with potential approval by Nov. 30 this year, as well as Fast Track Designation for pMN. If approved across the IgAN, pMN, and gMG indications, peak annual sales could reach $4 billion to $7 billion, according to equity analyst firm Argus.

For fiscal 2026, Vertex sales should rise about 10% to $13.3 billion, with net income coming in roughly even with 2025.

Both of these pharma giants can make a compelling argument for investors' dollars. Johnson & Johnson offers better value, based on its P/E and P/S ratios, and stands as the better buy for 2027.

Should you buy stock in Johnson & Johnson right now?

Before you buy stock in Johnson & Johnson, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Johnson & Johnson wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $327,620!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $959,410!*

Now, it’s worth noting Stock Advisor’s total average return is 802% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 17, 2026.

Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie, Genmab A/s, and Vertex Pharmaceuticals. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Nvidia reports tomorrow with an interim CEO — $108 billion is the easy numberNvidia closed at 162.85 on Friday, down 12.75% on the week and 32% below its 6 October record, with market value down to $3.92 trillion. The Q3 bar is $108 billion ±2%, and consensus already sits at $108.7 ~ 108.8 billion, so the revenue line is not where the surprise lives. The number that decides the reaction is the 71 ~ 72% Q4 gross-margin trough, followed by a Q4 guide against a $124.9 billion consensus. This piece prices the print, marks the 158.39 line and lays out the three scenarios in a table.
Author  Irene Q.
Nov 16, Mon
Nvidia closed at 162.85 on Friday, down 12.75% on the week and 32% below its 6 October record, with market value down to $3.92 trillion. The Q3 bar is $108 billion ±2%, and consensus already sits at $108.7 ~ 108.8 billion, so the revenue line is not where the surprise lives. The number that decides the reaction is the 71 ~ 72% Q4 gross-margin trough, followed by a Q4 guide against a $124.9 billion consensus. This piece prices the print, marks the 158.39 line and lays out the three scenarios in a table.
placeholder
Anthropic is six times oversubscribed at $1.4 trillion while Nvidia is down 32% — the AI trade has two pricesAnthropic lists on Nasdaq as ANT on Thursday at $70 ~ $78 a share, raising up to $64.4 billion at a target valuation near $1.4 trillion, and the book is reportedly six times covered. In the same six weeks, Nvidia has fallen 32% and the QQQ is 10.9% below its October peak. Private capital and public markets are marking the same AI complex at two very different prices. This piece separates the two books: what the S-1 shows, who is anchoring the $26 billion private placement, and what Thursday's debut would have to do to change the public tape.
Author  Irene Q.
Nov 16, Mon
Anthropic lists on Nasdaq as ANT on Thursday at $70 ~ $78 a share, raising up to $64.4 billion at a target valuation near $1.4 trillion, and the book is reportedly six times covered. In the same six weeks, Nvidia has fallen 32% and the QQQ is 10.9% below its October peak. Private capital and public markets are marking the same AI complex at two very different prices. This piece separates the two books: what the S-1 shows, who is anchoring the $26 billion private placement, and what Thursday's debut would have to do to change the public tape.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 16, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 16, 2026. Read on for the details.
Author  Mitrade
Nov 16, Mon
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 16, 2026. Read on for the details.
placeholder
Weekly Report: DXY 103.41, 10-year 5.15%, AUD carry 3bp — three FX regimes flipped in one weekThe dollar index rose 1.09% to 103.41, a 19-month high, while the US 10-year closed at 5.154% and the Australia-US two-year spread collapsed to about 3 basis points from 36. EURUSD fell 1.59% to 1.1024, USDJPY rose 1.51% to 159.78 and AUDUSD fell 1.79% to 0.6764, a 10-month low. Three FX regimes — the broad dollar, the US rate level and the Australian carry premium — flipped in the same week. This report marks the thresholds, ranks which one can flip back first, and lists the week's calendar.
Author  Irene Q.
Nov 16, Mon
The dollar index rose 1.09% to 103.41, a 19-month high, while the US 10-year closed at 5.154% and the Australia-US two-year spread collapsed to about 3 basis points from 36. EURUSD fell 1.59% to 1.1024, USDJPY rose 1.51% to 159.78 and AUDUSD fell 1.79% to 0.6764, a 10-month low. Three FX regimes — the broad dollar, the US rate level and the Australian carry premium — flipped in the same week. This report marks the thresholds, ranks which one can flip back first, and lists the week's calendar.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 17, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 17, 2026. Read on for the details.
Author  Mitrade
18 hours ago
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 17, 2026. Read on for the details.
goTop
quote